Cargando…
Evaluation of the appropriate use of commonly prescribed fluoroquinolones and the risk of dysglycemia
BACKGROUND: Fluoroquinolones are among the most widely prescribed antibiotics. However, concerns about increasing resistant microorganisms and the risk of dysglycemia associated with the use of these agents have emerged. OBJECTIVE: The primary objective of the study was to evaluate the appropriate u...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4410896/ https://www.ncbi.nlm.nih.gov/pubmed/25960658 http://dx.doi.org/10.2147/TCRM.S81280 |
_version_ | 1782368383826657280 |
---|---|
author | Kabbara, Wissam K Ramadan, Wijdan H Rahbany, Peggy Al-Natour, Souhaila |
author_facet | Kabbara, Wissam K Ramadan, Wijdan H Rahbany, Peggy Al-Natour, Souhaila |
author_sort | Kabbara, Wissam K |
collection | PubMed |
description | BACKGROUND: Fluoroquinolones are among the most widely prescribed antibiotics. However, concerns about increasing resistant microorganisms and the risk of dysglycemia associated with the use of these agents have emerged. OBJECTIVE: The primary objective of the study was to evaluate the appropriate use of commonly prescribed fluoroquinolones, including appropriate indication, dose, dose adjustment in renal impairment, and duration of treatment. The secondary objective was to investigate the dysglycemic effect of fluoroquinolone use (hypoglycemia and/or hyperglycemia) in diabetic and nondiabetic patients. METHODS: A prospective observational study at a teaching hospital in Lebanon was conducted over a 6-month period. A total of 118 patients receiving broad-spectrum fluoroquinolones (levofloxacin, ciprofloxacin, and moxifloxacin) were identified. Patients were mainly recruited from internal medicine floors and intensive care units. RESULTS: The final percentage for the appropriate indication, dose, and duration of fluoroquinolone therapy was 93.2%, 74.6%, and 57.6%, respectively. A total of 57.1% of the patients did not receive the appropriate dose adjustment according to their level of renal impairment. In addition, dysglycemia occurred in both diabetic and nondiabetic patients. Dysglycemia was more frequently encountered with ciprofloxacin (50.0%), followed by levofloxacin (42.4%) and moxifloxacin (7.6%). Hyperglycemia was more common than hypoglycemia in all groups. The highest incidence of hyperglycemia occurred with levofloxacin (70.0%), followed by ciprofloxacin (39.0%) and moxifloxacin (33.3%). In contrast, hypoglycemia did not occur in the ciprofloxacin group, but it was more common with moxifloxacin (11.1%) and levofloxacin (6.0%). CONCLUSION: The major clinical interventions for the future will adjust the dose and duration of therapy with commonly prescribed fluoroquinolones. The incidence of hypoglycemia was less common than hyperglycemia. |
format | Online Article Text |
id | pubmed-4410896 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-44108962015-05-08 Evaluation of the appropriate use of commonly prescribed fluoroquinolones and the risk of dysglycemia Kabbara, Wissam K Ramadan, Wijdan H Rahbany, Peggy Al-Natour, Souhaila Ther Clin Risk Manag Original Research BACKGROUND: Fluoroquinolones are among the most widely prescribed antibiotics. However, concerns about increasing resistant microorganisms and the risk of dysglycemia associated with the use of these agents have emerged. OBJECTIVE: The primary objective of the study was to evaluate the appropriate use of commonly prescribed fluoroquinolones, including appropriate indication, dose, dose adjustment in renal impairment, and duration of treatment. The secondary objective was to investigate the dysglycemic effect of fluoroquinolone use (hypoglycemia and/or hyperglycemia) in diabetic and nondiabetic patients. METHODS: A prospective observational study at a teaching hospital in Lebanon was conducted over a 6-month period. A total of 118 patients receiving broad-spectrum fluoroquinolones (levofloxacin, ciprofloxacin, and moxifloxacin) were identified. Patients were mainly recruited from internal medicine floors and intensive care units. RESULTS: The final percentage for the appropriate indication, dose, and duration of fluoroquinolone therapy was 93.2%, 74.6%, and 57.6%, respectively. A total of 57.1% of the patients did not receive the appropriate dose adjustment according to their level of renal impairment. In addition, dysglycemia occurred in both diabetic and nondiabetic patients. Dysglycemia was more frequently encountered with ciprofloxacin (50.0%), followed by levofloxacin (42.4%) and moxifloxacin (7.6%). Hyperglycemia was more common than hypoglycemia in all groups. The highest incidence of hyperglycemia occurred with levofloxacin (70.0%), followed by ciprofloxacin (39.0%) and moxifloxacin (33.3%). In contrast, hypoglycemia did not occur in the ciprofloxacin group, but it was more common with moxifloxacin (11.1%) and levofloxacin (6.0%). CONCLUSION: The major clinical interventions for the future will adjust the dose and duration of therapy with commonly prescribed fluoroquinolones. The incidence of hypoglycemia was less common than hyperglycemia. Dove Medical Press 2015-04-22 /pmc/articles/PMC4410896/ /pubmed/25960658 http://dx.doi.org/10.2147/TCRM.S81280 Text en © 2015 Kabbara et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Kabbara, Wissam K Ramadan, Wijdan H Rahbany, Peggy Al-Natour, Souhaila Evaluation of the appropriate use of commonly prescribed fluoroquinolones and the risk of dysglycemia |
title | Evaluation of the appropriate use of commonly prescribed fluoroquinolones and the risk of dysglycemia |
title_full | Evaluation of the appropriate use of commonly prescribed fluoroquinolones and the risk of dysglycemia |
title_fullStr | Evaluation of the appropriate use of commonly prescribed fluoroquinolones and the risk of dysglycemia |
title_full_unstemmed | Evaluation of the appropriate use of commonly prescribed fluoroquinolones and the risk of dysglycemia |
title_short | Evaluation of the appropriate use of commonly prescribed fluoroquinolones and the risk of dysglycemia |
title_sort | evaluation of the appropriate use of commonly prescribed fluoroquinolones and the risk of dysglycemia |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4410896/ https://www.ncbi.nlm.nih.gov/pubmed/25960658 http://dx.doi.org/10.2147/TCRM.S81280 |
work_keys_str_mv | AT kabbarawissamk evaluationoftheappropriateuseofcommonlyprescribedfluoroquinolonesandtheriskofdysglycemia AT ramadanwijdanh evaluationoftheappropriateuseofcommonlyprescribedfluoroquinolonesandtheriskofdysglycemia AT rahbanypeggy evaluationoftheappropriateuseofcommonlyprescribedfluoroquinolonesandtheriskofdysglycemia AT alnatoursouhaila evaluationoftheappropriateuseofcommonlyprescribedfluoroquinolonesandtheriskofdysglycemia |